The CANTOS study found that in enrolled patients with myocardial infarction with adequate lipid control, the use of a monoclonal antibody that targets IL‐1β and canakinumab further reduced the incidence of major cardiovascular events.5 The gene discussed is IL1B; the disease is myocardial infarction.